As of Feb 12
| +0.07 / +1.61%|
The 5 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 20.00, with a high estimate of 24.00 and a low estimate of 15.00. The median estimate represents a +353.51% increase from the last price of 4.41.
The current consensus among 5 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.